Trials / Unknown
UnknownNCT04429711
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19
Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection and to Decrease Viral Shedding - A Double Blind , Randomized Controlled Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Sheba Medical Center · Other Government
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Ivermectin which is an FDA-approved broad spectrum anti-parasitic agent, has also anti-viral activity. In vitro study have shown its activity against SARS-CoV-2, however its clinical effect on patients with COVID-19 never been tested. In this RCT we would like to evaluate the effect of Ivermectin on reduction of viral shedding among mild to moderate COVID-19 patients, and in shortening the symptom resolution time.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ivermectin Oral Product | 3mg Capsules, 12-15mg/ day for 3 days |
Timeline
- Start date
- 2020-05-12
- Primary completion
- 2020-09-30
- Completion
- 2020-10-31
- First posted
- 2020-06-12
- Last updated
- 2020-06-16
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT04429711. Inclusion in this directory is not an endorsement.